Rare diseases, affecting over 300 million patients globally, pose a significant public health challenge. These diseases have long faced challenges in terms of insufficient innovation resource allocation and inadequate investment support. Traditional investment models, characterized by their focus on short-term gains and risk aversion, struggle to meet the unique demands of the rare disease sector, which is marked by high risk, long cycles, and low commercial returns. Female investors, with their unique value concepts and investment behaviors, are becoming a crucial force in driving the innovative development of rare diseases. This study analyzes the behavioral patterns, value creation mechanisms, and practical approaches of female investors in rare disease investments, systematically explaining how they can inject new vitality into the rare disease innovation ecosystem through their socially responsible investment motives, long-term value-oriented strategies, and humanistic care influenced by emotional factors. The research finds that female investors exhibit unique methods of financial support, outstanding resource integration capabilities, and comprehensive value-added services, effectively addressing the shortcomings of traditional investment models in patient needs, social value creation, and sustainable development. However, female investors still face market-level issues such as funding scale limitations, insufficient decision-making influence, and professional skepticism, as well as policy environment constraints like inadequate regulatory policies and missing tax incentives, and social cognitive limitations. This study proposes systematic strategic recommendations for enhancing market capabilities, optimizing the policy environment, and improving social cognition, providing theoretical guidance and practical references to help female investors better play a promoting role.

Kathy Sun. A Study on the Role of Female Investors' Perspective in Promoting the Innovation and Development of Rare Diseases. International Journal of Frontiers in Medicine (2025), Vol. 7, Issue 3: 79-86. https://doi.org/10.25236/IJFM.2025.070311.

[1] Wang Li. Characteristics of Female Executives in Chinese Multinational Enterprises and Their Corporate ESG Ratings: A Feminist Care Ethics Perspective [D]. Sichuan: Southwestern University of Finance and Economics, 2024.

[2] Guo Wen. A Study on the Impact of Female Executives on Corporate ESG Performance [D]. Guangxi: Guangxi University, 2024.

[3] Zhang Lianxue and Liu Yuanli. The Current Situation and Countermeasures of China's Rare Disease Multi-Insurance Mechanism [J]. Rare Disease Research, 2025,4(1):7-13.

[4] Gu Yiwu, Wen Qiaorui, Liu Qikai, et al. Research Progress on Data Sharing of Rare Diseases Driven by Digital Intelligence [J]. Rare Disease Research, 2025,4(1):61-69.

[5] Zhang Jingqi, Zuo Liandong, Gao Xueqi, et al. —— Compliance Risk Management of Clinical Research on Rare Diseases in Children Initiated by Researchers: A Medical Institution Perspective [J]. Rare Disease Research, 2025,4(1):132-138.

[6] Mou Yan, Song Kui Meng, Wu Min, et al. Policy Text Analysis of China's Rare Disease Field from the Perspective of Policy Instruments [J]. Chinese Journal of Health Policy Research, 2021, 14(1):17-23.

[7] Gao Jiamin and Ma Zheng. The Relationship between Social Support and Quality of Life in Patients with Rare Diseases [J]. China Health Policy Research, 2020,13(4):38-44.

[8] Xie Shiyao, Liu Ziyu, and Li Shunping. The Current Status and Countermeasures of the Legal System for Rare Diseases in China [J]. Research on Rare Diseases, 2024,3(3):405-410.

[9] Chen Rui, Zhang Shuyang. Trends in Drug Development for Rare Diseases [J]. Rare Disease Research, 2024,3(2):221-223.

[10] Zhang Lei, Zou Linfeng, Ji Peili, et al. Investigation on the Status of Doctors Engaged in Rare Disease Work and Preliminary Discussion on the Training of Rare Disease Talents [J]. Rare Disease Research, 2024,3(3):400-404.